OTCMKTS:AMAR Amarillo Biosciences (AMAR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Amarillo Biosciences Stock (OTCMKTS:AMAR) 30 days 90 days 365 days Advanced Chart Get Amarillo Biosciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume6,100 shsAverage Volume18,253 shsMarket Capitalization$25.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Amarillo Biosciences (OTCMKTS:AMAR) is a biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of complex diseases. The company leverages its proprietary platform technologies and deep expertise in epigenetics, transcriptomics and proteomics to identify and validate drug targets that address unmet medical needs. Headquartered in Midland, Texas, Amarillo Biosciences operates a research laboratory that integrates computational biology, high-throughput screening and medicinal chemistry to advance its pipeline candidates from discovery through preclinical studies. The core business activities of Amarillo Biosciences include target identification, lead optimization and preclinical testing. The company’s proprietary libraries of small molecules are designed to modulate key biological pathways involved in cancer, inflammatory disorders and metabolic diseases. By focusing on epigenetic regulators and novel mechanisms of action, Amarillo aims to develop first-in-class or best-in-class drug candidates. Collaboration with academic institutions and contract research organizations allows the company to accelerate its discovery efforts and validate the safety and efficacy of its compounds in relevant disease models. Founded in 2013 as a spin-out from a prominent university research program, Amarillo Biosciences has built a multidisciplinary team of scientists, biochemists and drug development professionals. The leadership team is led by a chief executive officer with more than two decades of experience in pharmaceutical research and a chief scientific officer with a strong background in translational biology. Their combined expertise guides the company’s strategic direction and fosters a culture of innovation aimed at delivering impactful therapies. Amarillo Biosciences primarily serves the U.S. market but is actively exploring global partnerships to extend its research collaborations and clinical development programs. The company continues to seek opportunities for strategic alliances with biopharmaceutical firms and research foundations to advance its pipeline into human trials. As Amarillo progresses its lead candidates toward clinical milestones, it remains committed to leveraging cutting-edge science to address challenging therapeutic areas and improve patient outcomes.AI Generated. May Contain Errors. Read More Receive AMAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarillo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AMAR Stock News HeadlinesAmarillo native earns Rising Star awardJune 26, 2025 | msn.comAmarillo native, Navy veteran earns Rising Star Award for leadership in electric vehicle sectorJune 26, 2025 | msn.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | Brownstone Research (Ad)Vikings Acquire RB Cam Akers in Midseason Trade With TexansOctober 17, 2024 | msn.comFrance’s divided National Assembly votes to keep centrist speaker as political turmoil persistsJuly 20, 2024 | msn.comAmarillo, United States - Weather Forecasts | Maps | News - Yahoo WeatherMay 7, 2024 | yahoo.comTexas Rising Stars award honors two Amarillo lawyersApril 2, 2024 | msn.comRising Stars attorneys, Midland wildfire donations among this week's business newsMarch 31, 2024 | msn.comSee More Headlines AMAR Stock Analysis - Frequently Asked Questions How were Amarillo Biosciences' earnings last quarter? Amarillo Biosciences, Inc. (OTCMKTS:AMAR) released its earnings results on Wednesday, November, 14th. The company reported ($0.01) EPS for the quarter. The company earned $0.02 million during the quarter. How do I buy shares of Amarillo Biosciences? Shares of AMAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amarillo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amarillo Biosciences investors own include Fulcrum Therapeutics (FULC), Cerecor (CERC), Neos Therapeutics (NEOS), VIVUS (VVUS), AquaBounty Technologies (AQB), Astria Therapeutics (ATXS) and CymaBay Therapeutics (CBAY). Company Calendar Last Earnings11/14/2018Today7/12/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:AMAR CIK1014763 Webwww.amarbio.com Phone806-376-1741FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.45 million Net Margins-41,453.98% Pretax MarginN/A Return on EquityN/A Return on Assets-574.29% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.07 Sales & Book Value Annual Sales$20 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / BookN/AMiscellaneous Outstanding Shares42,066,000Free FloatN/AMarket Cap$25.24 million OptionableNot Optionable Beta-0.06 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:AMAR) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarillo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarillo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.